Recombinant production of omega-3 fatty acids by probiotic<i>E</i>scherichia<i>coli</i>Nissle 1917

Amiri-Jami, Mitra; Abdelhamid, Ahmed G.; Hazaa, Mahmoud; Kakùda, Yukio; Griffths, M.W.

doi:10.1093/femsle/fnv166

Cited by 28 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omega-3 PUFAs are considered as therapeutic options which may reduce secondary neuronal damage initiated by traumatic brain injury [ 2 ]. They also have a protective role in age-related macular degeneration, and can prevent the harmful effects of chronic stress [ 3 ], and may contribute to the prevention of cognitive decline [ 4 ]. In addition, benefits for bone health and turnover have been reported [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Enhanced eicosapentaenoic acid production by a new deep-sea marine bacterium Shewanella electrodiphila MAR441T

Zhang

Burgess

2017

PLoS ONE

View full text Add to dashboard Cite

Omega-3 fatty acids are products of secondary metabolism, essential for growth and important for human health. Although there are numerous reports of bacterial production of omega-3 fatty acids, less information is available on the biotechnological production of these compounds from bacteria. The production of eicosapentaenoic acid (EPA, 20:5ω3) by a new species of marine bacteria Shewanella electrodiphila MAR441T was investigated under different fermentation conditions. This strain produced a high percentage (up to 26%) of total fatty acids and high yields (mg / g of biomass) of EPA at or below the optimal growth temperature. At higher growth temperatures these values decreased greatly. The amount of EPA produced was affected by the carbon source, which also influenced fatty acid composition. This strain required Na+ for growth and EPA synthesis and cells harvested at late exponential or early stationary phase had a higher EPA content. Both the highest amounts (20 mg g-1) and highest percent EPA content (18%) occurred with growth on L-proline and (NH4)2SO4. The addition of cerulenin further enhanced EPA production to 30 mg g-1. Chemical mutagenesis using NTG allowed the isolation of mutants with improved levels of EPA content (from 9.7 to 15.8 mg g-1) when grown at 15°C. Thus, the yields of EPA could be substantially enhanced without the need for recombinant DNA technology, often a commercial requirement for food supplement manufacture.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced eicosapentaenoic acid production by a new deep-sea marine bacterium Shewanella electrodiphila MAR441T

Zhang

Burgess

2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Previous works have also shown different strategies for the simultaneous production of EPA and DHA: in Phaeodactylum tricornutum , a unicellular marine diatom, the heterologous coexpression of Δ6 desaturase and Δ5 elongase from Ostreococcus tauri resulted in 18% EPA and 11% DHA of TFA; in E. coli , the overexpression of the EPA/DHA pathway gene cluster from Shewanella baltica produced about 0.2–0.4% DHA and 14–31% EPA of TFA; , more recently, it has been reported that transgenic plants from Camelina sativa , a member of the Brassicacae, were able to accumulate about 4% of both DHA and EPA . However, most of these species have a low growth rate, thus generating low biomass yields.…”

Section: Resultsmentioning

confidence: 99%

Pathway Grafting for Polyunsaturated Fatty Acids Production in Ashbya gossypii through Golden Gate Rapid Assembly

2018

View full text Add to dashboard Cite

Here we present a Golden-Gate assembly system adapted for the rapid genomic engineering of the industrial fungus A. gossypii. This biocatalyst is an excellent biotechnological chassis for synthetic biology applications and is currently used for the industrial production of riboflavin. Other bioprocesses such as the production of folic acid, nucleosides, amino acids and biolipids have been recently reported in A. gossypii. In this work, an efficient assembly system for the expression of heterologous complex pathways has been designed. The expression platform comprises interchangeable DNA modules, which provides flexibility for the use of different loci for integration, selection markers and regulatory sequences. The functionality of the system has been applied to engineer strains able to synthesize polyunsaturated fatty acids (up to 35% of total fatty acids). The production of the industrially relevant arachidonic, eicosapentanoic and docosahexanoic acids remarks the high potential of A. gossypii to produce these functional lipids.

show abstract

“…Lactis mutant strains and Lcb. paracasei [196]. The possibility of creating E. coli Nissle 1917 probiotic strain with the ability to biosynthesize omega-3 fatty acids, particularly eicosapentaenoic and docosahexaenoic, is being investigated as well [197].…”

Section: Recombinant Probiotics As "Cell Factories" or For The Synthe...mentioning

confidence: 99%

Recombinant Probiotic Preparations: Current State, Development and Application Prospects

Khablenko

Danylenko

Yalovenko

et al. 2023

Innov Biosyst Bioeng

View full text Add to dashboard Cite

The article is devoted to the latest achievements in the field of research, development, and implementation of various types of medicinal products based on recombinant probiotics. The benefits of probiotics, their modern use in medicine along with the most frequently used genera and species of probiotic microorganisms were highlighted. The medicinal and therapeutic activities of the studied probiotics were indicated. The review suggests various methods of creating recombinant probiotic microorganisms, including standard genetic engineering methods, as well as systems biology approaches and new methods of using the CRISPR-Cas system. The range of potential therapeutic applications of drugs based on recombinant probiotics was proposed. Special attention was paid to modern research on the creation of new, more effective recombinant probiotics that can be used for various therapeutic purposes. Considering the vast diversity of therapeutic applications of recombinant probiotics and ambiguous functions, their use for the potential treatment of various common human diseases (non-infectious and infectious diseases of the gastrointestinal tract, metabolic disorders, and allergic conditions) was investigated. The prospects for creating different types of vaccines based on recombinant probiotics together with the prospects for their implementation into medicine were considered. The possibilities of using recombinant probiotics in veterinary medicine, particularly for the prevention of domestic animal diseases, were reviewed. The prospects for the implementation of recombinant probiotics as vaccines and diagnostic tools for testing certain diseases as well as modeling the work of the human digestive system were highlighted. The risks of creation, application, including the issues related to the regulatory sphere regarding the use of new recombinant microorganisms, which can potentially enter the environment and cause unforeseen circumstances, were outlined.

show abstract

Recombinant production of omega-3 fatty acids by probioticEscherichiacoliNissle 1917

Cited by 28 publications

References 30 publications

Enhanced eicosapentaenoic acid production by a new deep-sea marine bacterium Shewanella electrodiphila MAR441T

Enhanced eicosapentaenoic acid production by a new deep-sea marine bacterium Shewanella electrodiphila MAR441T

Pathway Grafting for Polyunsaturated Fatty Acids Production in Ashbya gossypii through Golden Gate Rapid Assembly

Recombinant Probiotic Preparations: Current State, Development and Application Prospects

Contact Info

Product

Resources

About